Clinical trials: Gastroesophageal Reflux (GER)
Gastroesophageal Reflux Disease (GERD)
Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients
This study is a phase III, multi-centre, randomized, double-blind study to assess the safety and tolerability of once daily treatment with esomeprazole 20 or 40 mg in pediatric and adolescent patients 12 to 17 years of age…
- Trial name
- NCT00241501
- Testing
- Esomeprazole (Nexium)
- Where
- 40 sites in United States, Canada and 2 more
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Acid Reflux, Gastro Oesophageal Reflux Disease
A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions
The purpose of this study is to assess the effectiveness of Zegerid 20mg capsules and powder and Losec 20mg capsules in healthy volunteers under fasting conditions.
- Trial name
- NCT01710995
- Testing
- Zegerid, Losec
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Norgine
Gastroesophageal Reflux Disease
The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity
The purpose of this study is to investigate the efficacy of lansoprazole combination with domperidone on intragastric acidity and intraesophageal acidity, GERD symptoms, impedance kinetics, gastric emptying in patients with…
- Trial name
- NCT02958046
- Testing
- Lansoprazole/Domperidone
- Where
- Turkey (Türkiye)
- Volunteers
- 12 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
GERD
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
The purpose of the study is to evaluate the efficacy and safety of arbaclofen placarbil (XP19986) compared to placebo in patients with gastroesophageal reflux disease.
- Trial name
- NCT00838396
- Testing
- XP19986 CR
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- Indivior Inc.
GERD, Cardiac Event
Cardiac Safety of Lansoprazole and Domperidon Combination
The aim of current study is to compare safety and efficacy of lansoprazole/domperidone 30/30 mg sustained release capsules (brand name: Duolans) and lansoprazole 30 mg micropellet capsules (brand name: Lasotab) in GERD patients…
- Conditions
- GERD, Cardiac Event, Safety Issues
- Trial name
- NCT03355170
- Testing
- Lansoprazole/Domperidone, Lansoprazole
- Where
- 16 sites in Turkey (Türkiye)
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Gastroesophageal Reflux Disease
PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects
Primary Objective: Pharmacodynamics: assessment by pH metry of the change in gastric pH (antacid activity) of Z0063, in comparison to the effect of Gaviscon Double Action Tablets, in healthy adult subjects.
- Trial name
- NCT03069963
- Testing
- Z0063, Gaviscon
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi
Gastro Esophageal Reflux
Efficacy and Safety of EsoDuo®
Clinical Trial to Evaluate the Effects of EsoDuo® in Controlling Reflux Symptoms Related to the Acid
- Trial name
- NCT06430047
- Testing
- EsoDuo® Tablet
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Gastroesophageal Reflux Disease
A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.
The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age.
- Trial name
- NCT00220818
- Testing
- Lansoprazole
- Volunteers
- 24 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease
Clinical Study, Multicenter, Randomized With 2 Arms of Pantoprazole + Domperidone and Pantoprazole Isolated at the Gastroesophageal Reflux Disease
This superiority phase III study to compare the combination of Pantoprazole and Domperidone with Pantoprazole isolated to the treatment of gastroesophageal reflux disease.
- Trial name
- PANDA (NCT01710462)
- Testing
- Pantoprazole + Domperidone, Pantozol®
- Where
- 8 sites in Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
GERD (Gastroesophageal Reflux Disease), NERD
New Topical tReatment Options for Symptomatic patiEnts With Nonerosive gastroesophageaL Reflux dIsease (The RELIEF Trial)
The goal of this randomized, double-blind, single-center clinical trial RELEIF is to learn if medical devices work to decrease symptoms of gastroesophageal reflux disease (GERD) in adults' patients.
- Conditions
- GERD (Gastroesophageal Reflux Disease), NERD, Heartburn, Regurgitation, Gastric
- Trial name
- RELIEF (NCT07624383)
- Testing
- Esophageal barrier medical device
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Cellmedis
Dyspepsia
The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.
"Functional dyspepsia" has been defined loosely as "pain or discomfort centered in the upper abdomen." The symptoms can also include fullness, early satiety, bloating, belching, nausea, retching and vomiting.
- Trial name
- NCT00303264
- Testing
- dexloxiglumide, Nexium (esomeprazole)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Forest Laboratories
Eosinophilic Esophagitis
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
This trial will study three doses of reslizumab versus placebo in children with eosinophilic esophagitis (EE). The objectives of the trial will be to study the effectiveness of reslizumab in improving the clinical signs and…
- Trial name
- NCT00538434
- Testing
- Reslizumab, Saline
- Where
- 37 sites in United States, Canada
- Volunteers
- 227 people
- Sponsor
- Ception Therapeutics
GERD
to Assess the Efficacy and Safety of the Probiotic E. Coli Strain M17 on Patients With GERD
The study is an Open Label, Prospective, Non Comparative, Pilot, clinical trial design. Patients with inadequate relief in GI symptoms associated with GERD despite PPI treatment will be screened and those who meet the inclusion…
- Trial name
- NCT00324532
- Testing
- ProBactrix
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- BioBalance Corporation
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy and safety of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg in subjects with erosive gastroesophageal reflux disease (eGERD).
- Trial name
- NCT00658632
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 85 sites in United States
- Volunteers
- 1,397 people
- Sponsor
- Eisai Inc.
Erosive Gastroesophageal Reflux Disease
JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD
The purpose of this study is to evaluate the effectiveness and safety of JAQBO® Tab. 20 mg(Zastaprazan citrate) patients who have been prescribed the investigational drug.
- Trial name
- NCT07115706
- Volunteers
- 7,150 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Gastroesophageal Reflux Disease
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
The primary objective of this study is to collect safety information on rabeprazole 10 mg and 20 mg in the treatment of gastroesophageal reflux disease (GERD) in children aged 12 to 16 years.
- Trial name
- NCT00132496
- Testing
- rabeprazole sodium
- Where
- 25 sites in United States
- Volunteers
- 111 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux
ASTERIX: Low Dose ASA and Nexium
The purpose of the study is to evaluate the effect of esomeprazole 20 mg od versus placebo for the prevention of gastric and/or duodenal ulcers in patients taking low-dose ASA.
- Trial name
- NCT00251966
- Testing
- Esomeprazole
- Where
- 94 sites in Australia, Bulgaria and 9 more
- Volunteers
- 960 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD)
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD)…
- Trial name
- NCT03561883
- Testing
- IW-3718, Standard-dose PPIs QD
- Where
- 101 sites in United States, Canada
- Volunteers
- 609 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Gastroesophageal Reflux, Gastric Ulcer
Safety of Rabeprazole in Patients Under Multiple Treatments
The purpose of this study is to evaluate the safety of rabeprazole 20mg/day in polymedicated patients and to examine the necessity of adjusted dosage in both therapies (rabeprazole and concomitant drug).
- Trial name
- NCT00511745
- Testing
- Rabeprazol
- Volunteers
- 2,157 people
- Sponsor
- Janssen-Cilag, S.A.
Chronic Posterior Laryngitis (CPL)
Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux
This study looks at how effective acid suppression therapy is on symptoms associated with chronic posterior laryngitis (CPL) in patients with documented pharyngeal acid reflux.
- Trial name
- NCT00628667
- Testing
- Esomeprazole
- Volunteers
- 120 people
- Sponsor
- AstraZeneca